{"id":"W4379650819","doi":"10.1136/annrheumdis-2023-eular.1464","title":"AB1591 POLICY DRIVERS FOR MARKET PENETRATION OF ANTI-TNF BIOSIMILARS: MULTI-COUNTRY COMPARISONS","year":2023,"lang":"en","type":"article","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University of Calgary; Centre for Advancing Health Outcomes; University of British Columbia","funders":"UCB Pharma; Jazz Pharmaceuticals; Nordic Pharma Group; Mylan; Biogen; Sanofi; Merck; Canadian Institutes of Health Research; Novartis; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biosimilar; Procurement; Infliximab; Medicine; Penetration (warfare); Market penetration; Market share; Business; Marketing; Operations research; Tumor necrosis factor alpha; Internal medicine; Engineering","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005049086,0.0001571218,0.0003540513,0.0002394471,0.0001233508,0.00001183104,0.0001987264,0.0003332981,0.0007633558],"category_scores_gemma":[0.0002573778,0.0001250903,0.0001566955,0.0005129605,0.0002679665,0.00005702591,0.00006735999,0.000133249,0.00006084957],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002400904,"about_ca_system_score_gemma":0.00007689327,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007754922,"about_ca_topic_score_gemma":0.0000700118,"domain_scores_codex":[0.9988437,0.0001281132,0.0003474321,0.0002716975,0.00003691405,0.0003721944],"domain_scores_gemma":[0.9991689,0.0003684795,0.0001088914,0.0002291672,0.00009472414,0.00002985904],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000173331,0.0002846536,0.01235642,0.00009475762,0.0003672606,0.000001399184,0.00009124716,0.00001031756,0.435949,0.005519588,0.541377,0.00377505],"study_design_scores_gemma":[0.004734788,0.0005040155,0.1974244,0.00006223186,0.0002384701,0.00001208728,0.0009322536,0.00388049,0.4025628,0.0004673759,0.3886135,0.0005675688],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5905412,0.004426131,0.2046807,0.07640939,0.01116414,0.01036128,0.008818123,0.003472077,0.09012695],"genre_scores_gemma":[0.9625626,0.0003646321,0.01938067,0.001667606,0.00008824329,0.00003435807,0.0002672792,0.00003085535,0.01560382],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3720213,"threshold_uncertainty_score":0.8358211,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04815369307898426,"score_gpt":0.3436926202255529,"score_spread":0.2955389271465687,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}